CalciMedica annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
CalciMedica Stock-Based Compensation Growth & History (CALC)
CalciMedica's stock-based compensation was $3.0M for fiscal 2025.
View full CalciMedica company overviewCalciMedica annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.0M | $658,000 | +28.45% |
| 2024 | 2024-12-31 | $2.3M | −$9.7M | −80.79% |
| 2023 | 2023-12-31 | $12.0M | $10.2M | +566.24% |
| 2022 | 2022-12-31 | $1.8M | −$3.6M | −66.38% |
| 2021 | 2021-12-31 | $5.4M | $3.6M | +200.62% |
| 2020 | 2020-12-31 | $1.8M | $1.1M | +142.28% |
| 2019 | 2019-12-31 | $738,000 | — | — |
CalciMedica quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $540,000 | −$635,000 | −54.04% |
| Q1 2026 | 2026-03-31 | $561,000 | $12,000 | +2.19% |
| Q4 2025 | 2025-12-31 | $622,000 | −$10,000 | −1.58% |
| Q3 2025 | 2025-09-30 | $625,000 | −$156,000 | −19.97% |
| Q2 2025 | 2025-06-30 | $1.2M | $689,000 | +141.77% |
| Q1 2025 | 2025-03-31 | $549,000 | $135,000 | +32.61% |
| Q4 2024 | 2024-12-31 | $632,000 | — | — |
| Q3 2024 | 2024-09-30 | $781,000 | $299,000 | +62.03% |
| Q2 2024 | 2024-06-30 | $486,000 | $23,000 | +4.97% |
| Q1 2024 | 2024-03-31 | $414,000 | −$10.7M | −96.28% |
| Q3 2023 | 2023-09-30 | $482,000 | $83,000 | +20.80% |
| Q2 2023 | 2023-06-30 | $463,000 | $142,000 | +44.24% |
| Q1 2023 | 2023-03-31 | $11.1M | $10.8M | +3221.19% |
| Q4 2022 | 2022-12-31 | $752,000 | −$751,000 | −49.97% |
| Q3 2022 | 2022-09-30 | $399,000 | −$1.0M | −72.12% |
| Q2 2022 | 2022-06-30 | $321,000 | −$991,000 | −75.53% |
| Q1 2022 | 2022-03-31 | $335,000 | −$794,000 | −70.33% |
| Q4 2021 | 2021-12-31 | $1.5M | $716,000 | +90.98% |
| Q3 2021 | 2021-09-30 | $1.4M | $870,000 | +155.08% |
| Q2 2021 | 2021-06-30 | $1.3M | $1.1M | +513.08% |
| Q1 2021 | 2021-03-31 | $1.1M | $903,000 | +399.56% |
| Q4 2020 | 2020-12-31 | $787,000 | — | — |
| Q3 2020 | 2020-09-30 | $561,000 | $311,000 | +124.40% |
| Q2 2020 | 2020-06-30 | $214,000 | — | — |
| Q1 2020 | 2020-03-31 | $226,000 | — | — |
| Q3 2019 | 2019-09-30 | $250,000 | — | — |
CalciMedica stock-based compensation trends
Over the last five fiscal years, CalciMedica's stock-based compensation increased from $1.8M to $3.0M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $540,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CalciMedica source filings ↗